Login to Your Account



Search

Search results

Pharma: Clinic roundup

Boehringer Ingelheim Corp. , of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, presented data from phase III studies of tiotropium delivered via the Respimat inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of ...

BioWorld Today - Staff - 2014-03-04 00:00 - 0 comments - 0 attachments

Clinic roundup

Chimerix Inc. , of Durham, N.C., released favorable data from presentations at the 2014 BMT Tandem Meetings related to its investigational antiviral with broad-spectrum activity, brincidofovir (CMX001). (BioWorld-Today-2014-03-03) ...

BioWorld Today - Staff - 2014-03-03 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Eisai Inc. , of Woodcliff Lake, N.J., said it started a phase III trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as first- or second-line treatment for HER2-negative locally recurrent or meta ...

BioWorld Today - Staff - 2014-02-28 00:00 - 0 comments - 0 attachments

Clinic roundup

Immune Design Corp. , of Seattle, reported the first patient has been treated in a phase I trial of ID-G305, a cancer immunotherapy. (BioWorld-Today-2014-02-28) ...

BioWorld Today - Staff - 2014-02-28 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Bristol-Myers Squibb Co. , of New York, and the Institute of Research in Immunology and Cancer in Montreal identified a molecule acting on a “novel therapeutic target” that was undisclosed. (BioWorld-Today-2014-02-27) ...

BioWorld Today - Staff - 2014-02-27 00:00 - 0 comments - 0 attachments

Clinic roundup

Altheus Therapeutics Inc. , of Oklahoma City, said it completed dosing in ZA201, a double-blind, active-controlled phase II trial evaluating the efficacy and safety of Zoenasa rectal gel vs. mesalamine enema in 120 patients with left-sided ulcerative ...

BioWorld Today - Staff - 2014-02-27 00:00 - 0 comments - 0 attachments

Clinic roundup

Hyperion Therapeutics Inc. , of Brisbane, Calif., said results of a phase II study of glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE) published in Hepatology showed that the trial met its primary endpoint, with sign ...

BioWorld Today - Staff - 2014-02-26 00:00 - 0 comments - 0 attachments

Clinic roundup

Celsion Corp. , of Lawrenceville, N.J., said the FDA reviewed and cleared the protocol for the company’s planned pivotal, double-blind, placebo-controlled phase III trial of Thermodox, its heat-activated liposomal encapsulation of doxorubicin in comb ...

BioWorld Today - Staff - 2014-02-25 00:00 - 0 comments - 0 attachments

Clinic roundup

Ignyta Inc. , of San Diego, said preliminary results were presented from the ongoing phase I dose escalation portion of a phase I/II trial of RXDX-101, Ignyta’s oral tyrosine kinase inhibitor targeting solid tumor indications, at the International As ...

BioWorld Today - Staff - 2014-02-24 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Janssen Research & Development LLC , of Raritan, N.J., part of Johnson & Johnson, started the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) phase III, global, multicenter study of Invok ...

BioWorld Today - Staff - 2014-02-24 00:00 - 0 comments - 0 attachments